Bimatoprost SR + LUMIGAN
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Open-Angle Glaucoma
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Trial Timeline
Jun 11, 2020 → May 14, 2022
NCT ID
NCT04285580About Bimatoprost SR + LUMIGAN
Bimatoprost SR + LUMIGAN is a phase 3 stage product being developed by AbbVie for Open-Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04285580. Target conditions include Open-Angle Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04285580 | Phase 3 | Completed |
Competing Products
20 competing products in Open-Angle Glaucoma